An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Although treatment options exist for people with urinary incontinence (UI), outcomes vary and there is insufficient information about the individual biologic and non-biologic factors that might affect treatment success, behaviors, and individual quality of life. With a variety of potential approaches, shared decision making is important to develop a treatment strategy that aligns with an individual’s preferences and goals of care and behaviors. All affected populations—female, male, children, neurogenic (congenital or acquired)—can benefit from individualized treatment approaches.
In March 2017, the National Institutes of Health (NIH) hosted Individualizing Treatment—Broadening the Framework for Urinary Incontinence Research, where participants reviewed numerous biologic and non-biologic factors that may influence individual treatment success and identified hypotheses and research questions to build the knowledge base that will enable better targeting of existing treatments to appropriate persons with UI. Read the March 2017 meeting summary(PDF, 501.12 KB)
Day 1: Thursday, Feb 1: 12:30pm – 5:30pm WebEx Link
Call-in toll number (US/Canada)
1-650-479-3208
Access code: 625 660 532
Call-in toll number (US/Canada)
1-650-479-3208
Access code: 623 938 508
Meeting Purpose
The goal of this meeting is to build on the ideas generated by the March 2017 meeting to develop fundable, interdisciplinary, investigator-initiated research proposals that will lead to better outcomes for currently available treatments by individualizing them to each patient, considering characteristics across the spectrum from biology to the social determinants of health. Adopting this broader framework for research will require engaging researchers from scientific fields beyond urology.
Meeting Objectives
Enhance interdisciplinary thinking among specialists and those with interest and involvement in UI research, including pelvic medicine and reconstructive surgeons, urologists, obstetrician-gynecologists, geriatricians, pediatricians, behavioral scientists, basic scientists, engineers, nurses, physical therapists, occupational therapists, administrators, and economists.
Expand participant understanding of the role of basic science, engineering, behavioral science, and clinical science in individualizing treatment for persons with UI and how it affects their caregivers and community.
Inform participants of novel research methodologies that can be used to study individualizing treatment and examine outcomes.
Discuss opportunities to involve families, peers, and other social network members of people with UI into research, treatment, and ongoing care.
Guide interdisciplinary research teams in the development of actionable research plans that will enable improved targeting of existing or novel UI treatments.
Provide time for research teams to confer with experts in clinical trial methodology and biostatistics regarding their research strategy.
Optional Pre-meeting Workshop for New Investigators
On the morning of February 1, prior to the main scientific session, the NIDDK is hosting an optional session, Establishing a Research Career in Benign Urologic Conditions. This optional workshop will review federal funding sources for research on benign urologic conditions, discuss strategies for balancing clinical care and research, and provide mentoring opportunities from senior investigators, among other activities. Interested participants can register to attend the pre-meeting workshop during the main meeting registration process.
Bring Your Research Team
Participants are encouraged to invite and bring colleagues from their institutions with diverse areas of expertise to facilitate interdisciplinary research planning. Having attended the March 2017 meeting is not necessary for participants to engage in or benefit from the February 2018 meeting. Participants are encouraged to review the Executive Summary of the March 2017 meeting at the link above.
Pre-Meeting Workshop: Establishing a Research Career in Benign Urologic Conditions
7:00 a.m. – 8:00 a.m.
Mentorship Breakfast
8:00 a.m. – 8:15 a.m.
Welcome and Workshop Objectives
Tamara Bavendam, M.D., M.S., NIDDK
8:15 a.m. – 8:30 a.m.
Getting the Most Out of NIH Meetings
Tamara Bavendam, M.D., M.S., NIDDK
Panel I: Balancing Research and Clinical Care
Moderator: Tracy Rankin, Ph.D., NIDDK
8:35 a.m. – 8:45 a.m.
Institutional Support for Your Research Career
Linda Brubaker, M.D., University of California, San Diego
8:45 a.m. – 8:55 a.m.
Establishing a Career in Clinical Urology Research
Leslee Subak, M.D., Stanford University
8:55 a.m. – 9:05 a.m.
Establishing a Career in Basic Urology Research
Adam Klausner, M.D., Virginia Commonwealth University
9:05 a.m. – 9:15 a.m.
Establishing a Career in Urologic Health Services Research
William Stuart Reynolds, M.D., M.P.H., Vanderbilt University
9:15 a.m. – 9:50 a.m.
Moderated Discussion and Audience Q&A
9:50 a.m. – 10:05 a.m.
Break
Panel II: Paths to Funding for New Researchers
Moderator: Jenna Norton, M.P.H., NIDDK
10:10 a.m. – 10:15 a.m.
Funding Opportunities in Benign Urologic Conditions at the NIDDK
Tracy Rankin, Ph.D., NIDDK
10:15 a.m. – 10:20 a.m.
Funding Opportunities in Benign Urologic Conditions at the National Institute on Aging (NIA)
Marcel Salive, M.D., M.P.H., NIA
10:20 a.m. – 10:25 a.m.
Funding Opportunities in Benign Urologic Conditions at the National Institute of Nursing Research (NINR)
Karen Huss, Ph.D., R.N., NINR
10:25 a.m. – 10:30 a.m.
Funding Opportunities in Benign Urologic Conditions at the National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Michael Wolfson, Ph.D., NIBIB
10:30 a.m. – 10:35 a.m.
Funding Opportunities in Benign Urologic Conditions at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Donna Mazloomdoost, M.D., NICHD
10:35 a.m. – 10:40 a.m.
Funding Opportunities in Benign Urologic Conditions at the National Center for Complementary and Integrative Health (NCCIH)
Lanay Mudd, Ph.D., NCCIH
10:40 a.m. – 10:50 a.m.
Funding Sources Beyond NIH: A SUFU-funded Research Project
Rahel Nardos, M.D., Oregon Health & Science University
10:50 a.m. – 11:00 a.m.
Funding Sources Beyond NIH: An AUGS-funded Research Project
Vivian Sung, M.D., Women & Infants Hospital in Rhode Island
11:00 a.m. – 11:10 a.m.
Funding Sources Beyond NIH: An AUA-funded Research Project
A. Lenore Ackerman, M.D., Ph.D., Cedars-Sinai Medical Center
Session I: Novel Research Methodologies—Database Analysis
Moderator: Rahel Nardos, M.D., Oregon Health & Science University
12:55 p.m. – 1:15 p.m.
Developing Risk Profiles for Benign Urologic Conditions
Matthew Barber, M.D., M.H.S., Duke University School of Medicine
1:15 p.m. – 1:35 p.m.
Predictive Modeling in Neuroimaging: What Can We Apply to Research on Benign Urologic Conditions?
Damien Fair, Ph.D., PA-C, Oregon Health & Science University
1:35 p.m. – 1:55 p.m.
Moderated Discussion and Audience Q&A
Session II: Novel Research Methodologies—Trial Designs
Moderator: William Stuart Reynolds, M.D., M.P.H., Vanderbilt University
2:00 p.m. – 2:20 p.m.
Applying Master Protocols to Enhance Trial Design
Janet Woodcock, M.D., U.S. Food and Drug Administration (FDA)
2:20 p.m. – 2:40 p.m.
Getting SMART About Adaptive Interventions in Benign Urologic Conditions Research
Daniel Almirall, Ph.D., University of Michigan
2:40 p.m. – 3:00 p.m.
Moderated Discussion and Audience Q&A
3:00 p.m. – 3:15 p.m.
Break
Session III: Identifying and Working with Collaborators
Moderator: Linda Brubaker, M.D., University of California, San Diego
3:20 p.m. – 3:30 p.m.
Engaging Psychometricians in Benign Urologic Conditions Research
Kathryn Flynn, Ph.D., Medical College of Wisconsin
3:30 p.m. – 3:40 p.m.
Engaging Behavioral Scientists and Public Health Practitioners in Benign Urologic Conditions Research
Sonya Brady, Ph.D., University of Minnesota School of Public Health
3:40 p.m. – 3:50 p.m.
Engaging Primary Care Providers in Benign Urologic Conditions Research
Michelle Seelig, M.D., M.S., University of Washington
3:50 p.m. – 4:00 p.m.
Engaging Physical Therapists in Benign Urologic Conditions Research
Meryl Alappattu, Ph.D., D.P.T., University of Florida
4:00 p.m. – 4:10 p.m.
Engaging Basic Scientists and Engineers in Benign Urologic Conditions Research
Margot Damaser, Ph.D., Cleveland Clinic
4:10 p.m. – 4:45 p.m.
Moderated Discussion and Audience Q&A
Session IV: Elevator Pitches*
Moderator: Jenna Norton, M.P.H., NIDDK
5:30 p.m. – 6:30 p.m.
Poster Session
6:30 p.m.
Meeting Recess and Networking Dinners
*Sign up during meeting registration to give a 2-minute “elevator pitch” for your research idea to identify potential collaborators.
An elevator pitch is the brief speech you might give to a potential collaborator if you ran into them on an elevator. What would you say to capture their imagination before the elevator doors open and she/he steps off? This 2-minute speech should explain what you hope to achieve and who/what you need to accomplish that goal.
February 2, 2018
8:00 a.m. – 9:00 a.m.
Mentorship Breakfast
Session V: Translational Pathway for Individualized Therapies
Bench to Bedside Models in Cardiovascular Precision Medicine Research
W.H. Wilson Tang, M.D., Cleveland Clinic
9:35 a.m. – 9:45 a.m.
Bench to Bedside Development of a Treatment for Urinary Incontinence
Michael Chancellor, M.D., Advanced Urology Institute
9:45 a.m. – 9:55 a.m.
Prevalent Myths in the Pharmacological Management of Incontinence
Jeremy Heaton, M.D., Astellas
9:55 a.m. – 10:05 a.m.
Implantable Medical Device for Treatment of Urologic Conditions with Onboard Distributed Closed-Loop Research Capability
Lance Zirpel, Ph.D., Medtronic
10:05 a.m. – 10:15 a.m.
Developing Individualized Treatments for Benign Urologic Conditions: FDA Considerations
Roger Wiederhorn, M.D., FDA
10:15 a.m. – 11:00 a.m.
Moderated Discussion and Audience Q&A
11:00 a.m. – 11:15 a.m.
Break
11:15 a.m. – 1:15 p.m.
Team-based Research Planning Session and Working Lunch
Moderator: Carolyn Best, Ph.D., American Urological Association
Work with your team to develop your research question into a research plan. Meeting speakers and NIH staff will be available to provide feedback and answer questions as you plan.
1:15 p.m.
Meeting Adjournment
1:30 p.m.
Post-meeting Expert Consultation Sessions
(Sign up for feedback from NIH staff and senior investigators)
Sign up with your collaborative research team during registration for a 15-minute session during which you can share your research idea and receive feedback from NIH staff and senior investigators.
Abstracts
Attendees are invited to submit abstracts for posters to be presented at the end of the first day. Posters can be of two varieties:
Traditional—Presenting research that can improve our ability to individualize treatment for patients with UI. Posters do not need to focus on treatment of urinary incontinence.
Idea Generating—Building the case for a factor that might affect treatment outcomes and help target treatments, including why it should be considered in research.
The goal of the poster session will be to stimulate interdisciplinary thinking and create additional ideas to prepare for small group discussions the following day.
Following the poster session, there will be opportunities for small groups of individuals to go out to dinner to continue the discussions.
Submission Deadline
January 22, 2018, 5:00 p.m.
Submitting Abstracts
All abstracts must be submitted via email to Mark Dennis of The Scientific Consulting Group, Inc. Abstract submissions should be no longer than 250 words (not including name and affiliation). Download the Abstract Template(DOCX, 24.67 KB) .
Formatting Requirements
Please follow the instructions below to format an abstract. (Note: Submissions will not be edited for spelling or grammar and will be accepted “as is.”)
The abstract should be an MS Word document typed single-spaced using Times New Roman font. Everything but the title should be in normal, 12-point font.
The abstract’s title should be Bold, 16-Point, Title Case font and should clearly represent the nature of the investigation.
On the line after the title, list the author’s first and last names, degree, affiliation, city, state, and country.
Separate multiple authors with a semicolon, and underline the primary author’s name (one primary author per abstract).
Use one blank line between the title and the body of the abstract and between paragraphs.
The abstract file name should follow this format: LastNameofprimary author_FirstWordOfTitle (e.g., Zucker_Effects).
Please ensure that your abstract is the correct length and use 1-inch margins.
Use of standard abbreviations is desirable (e.g., LUTS), as well as standard symbols for units of measure (e.g., kg, g, mg, mL, L, and %). Place any special or unusual abbreviations in parentheses after the full word the first time that it appears. Use numerals to indicate numbers except to begin sentences. Do not use subheadings (e.g., Methods, Results).
Simple tables or graphs may be included; however, they must fit within the designated abstract space of one page.
Poster Presentations
Posters will be displayed on 4-foot-high by 6-foot-wide poster boards. Pushpins and Velcro will be provided onsite. The recommended poster size is 3 feet by 5 feet.
Event Logistics
Registration
Registration Closed
Registration ended
Location
Natcher Conference Center Building 45 45 Center Drive, NIH Campus Bethesda20894
